Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations

Medicine, Pathology, Gastroenterology +16

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Arun J. Sanyal, Naga Chalasani, Kris V. Kowdley et al. · New England Journal of Medicine · 2010 · 3.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7

A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis

Renata Belfort, Stephen A. Harrison, Kenneth Brown et al. · New England Journal of Medicine · 2006 · 1.8K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant Mice

Li Yu, Shanqin Xu, Maria M. Mihaylova et al. · Cell Metabolism · 2011 · 1.7K citations · Full text

Life Sciences, Biochemistry, Cell Biology +17

Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins

Weijia Kong, Jing Wei, Parveen Abidi et al. · Nature Medicine · 2004 · 1.4K citations

Pharmacy, Pharmacology, Pharmacotherapy +4